Analyst firms · Barclays · CHWY
Barclays CHWY price target and rating history
Chewy Inc. (CHWY) · Consumer Discretionary
Barclays rates Chewy Inc. (CHWY) Overweight with a $30 price target, as of its latest action on Jan 11, 2024. It has published 4 rating actions on CHWY since September 2021, including 1 upgrade and 0 downgrades. Across 4 firms with a CHWY price target in the last 12 months, the median target is $25.
- Current rating
- Overweight
- Price target
- $30
- Median target, all firms
- $25
- Actions on CHWY
- 4
Barclays price target on CHWY
Every Barclays rating on CHWY
- Jan 11, 2024
- Aug 31, 2023
- Dec 10, 2021
- Sep 2, 2021
How other firms rate CHWY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Stifel | Hold | $22 | Nov 17, 2026 |
| Evercore ISI | In-line | $25 | Sep 10, 2026 |
| Rosenblatt | Neutral | $25 | Aug 20, 2026 |
| MoffettNathanson | Neutral | Jun 11, 2026 | |
| Raymond James | Outperform | $28 | Feb 19, 2026 |
Questions about Barclays and CHWY
- What is Barclays's price target for CHWY?
- Barclays's latest stated price target for Chewy Inc. (CHWY) is $30, from its action on Jan 11, 2024.
- What is Barclays's rating on CHWY?
- Barclays rates CHWY Overweight, a bullish rating, as of Jan 11, 2024.
- When did Barclays last change its view on CHWY?
- On Jan 11, 2024, Barclays upgrades to Overweight from Equal Weight, price target $19 to $30.
- How does Barclays's CHWY target compare with other analysts?
- Across 4 firms with a CHWY price target in the last 12 months, the median target is $25.
More CHWY rating histories
- Evercore ISI3
- MoffettNathanson3
- Raymond James3
- Deutsche Bank3
- Mizuho4
- Jefferies4
- Argus Research4
- Wolfe Research4
- BNP Paribas Exane3
- Citigroup3
- Needham4
- Piper Sandler4
- Goldman Sachs4
- Morgan Stanley4
- UBS3
- Oppenheimer3
- Robert W. Baird3
- Wedbush5
All Barclays ratingsCHWY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.